| REVIEW ARTICLE |
|
| Year : 2014 | Volume
: 16
| Issue : 1 | Page : 7-9 |
|
|
Schizophrenia : Current concepts in aetiology
PS Bhat1, Puneet Khanna2, KJ Divinakumar3
1 Senior Advisor (Psychiatry), INHS Asvini, Colaba, Mumbai, Pin - 400005, India
2 Resident (Psychiatry), INHS Asvini, Colaba, Mumbai, Pin - 400005, India
3 Classified Specialist (Psychaitry), INHS Asvini, Colaba, Mumbai, Pin - 400005, India
Correspondence Address:
P S Bhat
Senior Advisor (Psychiatry), INHS Asvini, Colaba, Mumbai, Pin - 400005
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0975-3605.203348
|
|
|
Schizophrenia is perhaps the most devastating neuropsychiatric illness. Worldwide, its prevalence rate is about 1%. Schizophrenia is considered a neurodevelopmental disorder involving the interplay of susceptibility genes and environmental factors. There is a wide range of pathologic findings, but there is no specific or diagnostic laboratory abnormality. Till date, the aetiology, neuropathology, and pathophysiology of schizophrenia remain elusive. Over the last forty years, the dopaminergic model has been the leading neurochemical hypothesis of schizophrenia. Yet it remains unlikely that dopaminergic dysfunction, on its own. Glutamatergic models provide an alternate approach for conceptualizing the brain abnormalities associated with schizophrenia. New pharmacological and behavioral approaches aimed at potentiating glutamatergic neurotransmission, offer new hopeforfuture clinical development
|
|
|
|
| [PDF]* |
|
 |
|
